Overview
Study to Test an Approved Product in the Early Treatment of Migraine (0462-066)
Status:
Completed
Completed
Trial end date:
2005-04-04
2005-04-04
Target enrollment:
0
0
Participant gender:
All
All
Summary
The purpose of this study is to test the effectiveness of an approved drug in the early treatment of migraine.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Merck Sharp & Dohme Corp.Treatments:
Rizatriptan
Criteria
Inclusion Criteria:- Six month history of migraine; attacks typically mild when they begin with 1-4
migraine attacks per month.
Exclusion Criteria:
- Heart disease
- High blood pressure